rethinkTHC Search
Menu
Study breakdown

Mouse study suggests endocannabinoid receptors help mediate anti-inflammatory effects in colitis

Animal StudyPreliminary evidence
The takeaway

Blocking CB1 or CB2 cannabinoid receptors reversed the anti-inflammatory effects of a muscarinic receptor drug in a mouse model of colitis, suggesting the endocannabinoid system plays a role in gut inflammation control.

Researchers and readers interested in the endocannabinoid system's role in gut inflammation and inflammatory bowel disease.

Blocking either CB1 or CB2 receptors reversed the anti-inflammatory benefits in colitis

What the researchers found

When researchers administered CB1 or CB2 receptor antagonists before treating colitis-induced mice with McN-A-343 (a muscarinic receptor agonist), the drug's anti-inflammatory benefits were significantly reversed, with increased intestinal damage, pro-inflammatory cytokines, oxidative stress, and NF-kB expression.

Why it matters

Ulcerative colitis affects millions worldwide and current treatments have significant limitations. This study reveals crosstalk between the cholinergic and endocannabinoid systems in gut inflammation, opening a potential new pathway for therapeutic development.

The numbers in context

Both AM251 (CB1 antagonist, 3.0 mg/kg) and AM630 (CB2 antagonist, 1.0 mg/kg) significantly reversed McN-A-343's effects, increasing myeloperoxidase levels, TNF-alpha, IL-1beta, malondialdehyde, nitrate/nitrite, and protein expression of NF-kB, iNOS, and COX-2.

How the study worked

Male mice received acetic acid-induced colitis, then were treated with the M1 muscarinic receptor agonist McN-A-343. CB1 antagonist AM251 and CB2 antagonist AM630 were given 30 minutes before treatment. After 18 hours, colon tissue was analyzed for macroscopic and microscopic damage, inflammatory markers, oxidative stress, and protein expression via Western blot.

What this study cannot tell us

This is a mouse model using chemically induced colitis, which does not fully replicate human ulcerative colitis. Only male mice were used. The acute 18-hour timeframe does not reflect chronic disease. Dexamethasone was the only comparator.

How to read the evidence

Single animal study using chemically induced colitis in male mice only, with an acute timeframe.

When this study was published

Published in 2025.

The bigger picture

The finding that cannabinoid receptors are required for the anti-inflammatory action of a non-cannabinoid drug reveals that the endocannabinoid system may be a more central player in gut inflammation pathways than previously appreciated. This crosstalk could inform combination therapy approaches.

Questions still open

  • Would direct cannabinoid agonists produce similar or greater anti-inflammatory effects in this model? Does this crosstalk exist in human colonic tissue? Could combination therapy targeting both systems offer advantages over current IBD treatments?

Common questions

What does this mean for people with colitis?
It suggests the endocannabinoid system plays a role in controlling gut inflammation, which could eventually inform new treatment approaches. However, this is a mouse study and direct clinical implications are far off.
Did they test cannabis or cannabinoids directly?
No. They tested a muscarinic receptor drug and found that its anti-inflammatory effects depended on intact cannabinoid receptor signaling, demonstrating crosstalk between the two systems.

Read the original research

Crosstalk between M1 muscarinic acetylcholine receptor and endocannabinoid system promotes attenuation of inflammation in ulcerative colitis.

European journal of pharmacology, 1008, 178368

Citation

de Aguiar Magalhães, Diva; Guimarães Sousa, Stefany; da Silva Monteiro, Carlos Eduardo; Arruda Batista, Jalles; de Sousa, Antônio Kleiton; Dos Santos Ferreira, Jayro; Carvalho Pereira, Cynthia Maria; do Nascimento Lima, José Victor; da Silva Sousa, João Janilson; da Silva Prudêncio, Rafael; Lino da Silva, Tino Marcos; Oliveira Silva, Francisca Géssica; Franco, Alvaro Xavier; Di Lenardo, David; Pereira Vasconcelos, Daniel Fernando; Almeida Rocha, Jefferson; Alves Figueiredo, Kayo; Gomes Soares, Pedro Marcos; Dos Reis Barbosa, André Luiz. (2025). Crosstalk between M1 muscarinic acetylcholine receptor and endocannabinoid system promotes attenuation of inflammation in ulcerative colitis.. European journal of pharmacology, 1008, 178368. https://doi.org/10.1016/j.ejphar.2025.178368

Explore the wider topic